Phase 1 Refractory Multiple Myeloma Clinical Trials
50 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 50 trials
Recruiting
Phase 1Phase 2
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals150 enrolled4 locationsNCT07455851
Recruiting
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Relapsed or Refractory Multiple Myeloma
Genentech, Inc.120 enrolled14 locationsNCT05927571
Recruiting
Phase 1
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
National Cancer Institute (NCI)26 enrolled14 locationsNCT06465316
Recruiting
Phase 1
Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease
Relapsed/Refractory Multiple Myeloma
Peter MacCallum Cancer Centre, Australia12 enrolled1 locationNCT07541391
Recruiting
Phase 1Phase 2
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Phase 1
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Opna Bio LLC130 enrolled12 locationsNCT06433947
Recruiting
Phase 1Phase 2
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Refractory Multiple MyelomaRelapse Multiple Myeloma
Natalie Callander62 enrolled1 locationNCT07479979
Recruiting
Phase 1
TriPRIL CAR T Cells in Multiple Myeloma
Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
Marcela V. Maus, M.D.,Ph.D.18 enrolled1 locationNCT05020444
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled84 locationsNCT04973605
Recruiting
Phase 1
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC80 enrolled15 locationsNCT06604715
Recruiting
Phase 1Phase 2
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Phase 1
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
David Avigan25 enrolled1 locationNCT07377435
Recruiting
Phase 1
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
David Avigan25 enrolled2 locationsNCT06799026
Recruiting
Phase 1
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Roswell Park Cancer Institute15 enrolled1 locationNCT06622005
Recruiting
Phase 1Phase 2
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals186 enrolled7 locationsNCT06669247
Recruiting
Phase 1
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Massachusetts General Hospital25 enrolled3 locationsNCT07032714
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA200 enrolled32 locationsNCT05862012
Recruiting
Phase 1Phase 2
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Fred Hutchinson Cancer Center30 enrolled1 locationNCT07181941